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Abstract
Bacteriophage lytic enzymes have recently attracted considerable interest as novel antimicrobials against Gram-positive
bacteria. In this work, antimicrobial activity in milk of HydH5 [a virion-associated peptidoglycan hydrolase (VAPGH) encoded
by the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88], and three different fusion proteins created between
HydH5 and lysostaphin has been assessed. The lytic activity of the five proteins (HydH5, HydH5Lyso, HydH5SH3b,
CHAPSH3b and lysostaphin) was confirmed using commercial whole extended shelf-life milk (ESL) in challenge assays with
104 CFU/mL of the strain S. aureus Sa9. HydH5, HydH5Lyso and HydH5SH3b (3.5 mM) kept the staphylococcal viable counts
below the control cultures for 6 h at 37uC. The effect is apparent just 15 minutes after the addition of the lytic enzyme. Of
note, lysostaphin and CHAPSH3b showed the highest staphylolytic protection as they were able to eradicate the initial
staphylococcal challenge immediately or 15 min after addition, respectively, at lower concentration (1 mM) at 37uC.
CHAPSH3b showed the same antistaphyloccal effect at room temperature (1.65 mM). No re-growth was observed for the
remainder of the experiment (up to 6 h). CHAPSH3b activity (1.65 mM) was also assayed in raw (whole and skim) and
pasteurized (whole and skim) milk. Pasteurization of milk clearly enhanced CHAPSH3b staphylolytic activity in both whole
and skim milk at both temperatures. This effect was most dramatic at room temperature as this protein was able to reduce
S. aureus viable counts to undetectable levels immediately after addition with no re-growth detected for the duration of the
experiment (360 min). Furthermore, CHAPSH3b protein is known to be heat tolerant and retained some lytic activity after
pasteurization treatment and after storage at 4uC for 3 days. These results might facilitate the use of the peptidoglycan
hydrolase HydH5 and its derivative fusions, particularly CHAPSH3b, as biocontrol agents for controlling undesirable bacteria
in dairy products.
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Introduction
Staphylococcus aureus is a bacterial pathogen responsible for a wide
range of human and animal infections, including food poisoning
caused by the ingestion of enterotoxins produced in food by
enterotoxigenic strains [1,2]. Staphylococcal enterotoxins are
notoriously thermostable and maintain their stability even after
the thermal treatments customarily utilized in the food industry.
This represents a threat to consumers and makes necessary the
control of staphylococcal contaminants to avoid the production of
high risk levels of enterotoxins [3].
Humans and domestic animals are the primary reservoirs of S.
aureus, as this microorganism colonizes mucous membranes and
skin. Thus, food handlers and animals are usually the primary
source of S. aureus contamination of food products of animal origin
[4]. S. aureus is also an important etiological agent of mastitis in
cattle, goats and sheep [5], with the mastitic udder being a source
of contaminated milk and milk-derived dairy products, along with
the dairy farm environment and processing facilities [6]. Although
an important food safety concern, S. aureus mastitis is difficult to
eradicate and constitutes a serious economic problem for dairy
herd management [7]. Several antimicrobial treatments are
available for clinical mastitis differing in the antimicrobial agent,
route of application, duration, probability of cure or recurrence,
and cost [8]. However, this problem remains unsolved in part due
to the ability of S. aureus to invade and reside intracellularly [9],
within mammary cells, thereby evading most antibiotics, but also
because of the high frequency of antibiotic resistance among S.
aureus strains [10,11].
Bacteriophage endolysins have been proposed as antimicrobials
to control Gram positive bacteria due to their ability to degrade
the bacterial cell wall resulting in lysis of the pathogen [12]. This
bactericidal activity has been successfully used to control
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antibiotic-resistant pathogenic bacteria in animal models [13]. For
instance, the pneumococcal lysin Cpl-1 protected a mouse model
against pneumococcal bacteraemia and colonization by intrave-
nous administration and topical nasal treatment, respectively [14].
More recently, staphylococcal lysins have also been used against
staphylococcal infections in mouse models. This is the case for
endolysins MV-L [15], LysGH14 [16] or the chimeric lysin ClyS
[17] that protected mice against lethal doses of methicillin-resistant
S. aureus (MRSA) by intraperitoneal injections. The effectiveness
shown by the staphylococcal phage K endolysin, LysK, CHAP
domain construct and the CHAP domain construct from the
phage K tail-associated muralytic enzyme to eliminate S. aureus
from the nares of challenged mice and rats, respectively, supports
the potential use of phage lytic proteins’ catalytic domains as
antimicrobials [18,19].
Lysostaphin is a well characterized peptidoglycan hydrolase
produced by Staphylococcus simulans biovar. staphylolyticus. Its lytic
action against S. aureus relies mainly on its N- terminal domain
with glycylglycine endopeptidase activity that cleaves the penta-
glycine cross bridges present in staphylococcal peptidoglycan,
while its C- terminal domain promotes its specific binding to
staphylococcal peptidoglycan [20]. It was shown to protect
mammary glands against S. aureus challenge in both mice [21]
and cattle [22]. It has also been shown that antimicrobial synergy
exists in vitro between some phage endolysins and antibiotics or
antimicrobial peptides of bacterial origin against S. aureus
[18,23,24]. In this regard, the in vitro synergy observed between
phage lytic proteins and lysostaphin was recently expanded to
include the in vivo protection of murine mammary glands from an
S. aureus challenge [25].
In addition to mammary gland protection, phage endolysins
might also serve to inhibit undesirable bacterial growth for food
biocontrol purposes [24]. The staphylococcal phage vB_SauS-
phiIPLA88 endolysin, LysH5, has been demonstrated to control S.
aureus growth in milk. The purified protein was able to rapidly kill
S. aureus growing in pasteurized milk with a 106 CFU/ml
inoculum undetectable after 4 h of co-incubation with 1.6 mM
LysH5 at 37uC [26].
In addition to endolysins, there is a largely untapped group of
phage lytic proteins the virion-associated peptidoglycan hydrolases
(VAPGHs) that are involved in local cell-wall degradation to
facilitate the injection of phage DNA into the cell cytoplasm [27].
These PGHs have been reported to be encoded by phages
infecting S. aureus [28,29] and other bacterial species [30–33].
Their antimicrobial activity was first postulated in 1940, with ‘lysis
from without’ that takes place when a very high number of phages
are adsorbed onto the host cell [34].
In a previous work, we have described the VAPGH HydH5
encoded by the S. aureus phage vB_SauS-phiIPLA88. Bioinfor-
matic analysis of the protein sequence revealed two putative
domains, a cysteine, histidine-dependent amidohydrolase/pepti-
dase (CHAP) domain [35,36]; and a LYZ2 (lysozyme subfamily 2)
domain [28], which conferred antimicrobial activity against
S. aureus [37]. Three different fusion proteins obtained between
lysostaphin and HydH5 (CHAPSH3b, HydH5SH3b and HydH5-
Lyso) showed significantly greater activity than the parental
protein HydH5, and lysed both bovine and human S. aureus,
including MRSA N315, and human Staphylococcus epidermidis strains
[38].
In this work, we have assessed the antimicrobial ability of
HydH5 and its derivative fusion proteins in milk, in order to
explore new biopreservation strategies to effectively inhibit S.
aureus growth in dairy products.
Materials and Methods
Bacterial Strains and Culture Conditions
S. aureus Sa9, isolated from a mastitic milk sample, was used as
the indicator strain for lytic activity [39]. This bacterium was
grown in TSB broth (Tryptic Soy Broth, Difco, Franklin Lakes,
NJ, US) at 37uC for up to 18 h with vigorous shaking. For selective
counting Baird–Parker agar supplemented with egg yolk tellurite
(Scharlau Chemie, S.A. Barcelona, Spain) was used in commercial
whole extended shelf life (ESL) (125uC, 4 sec) milk samples, and
ChromoID S. aureus plates (Biome´rieux, Marcy l’Etoile, France) in
raw and pasteurized (72uC, 15 sec) (whole and skim) milk samples.
E. coli BL21(DE3)/pLysS containing the pET21a-HydH5 and
derivative plasmids were used to overproduce the lytic proteins
HydH5, HydH5SH3b, HydH5Lyso and CHAPSH3b [38].
Microbiological and Physicochemical Analyses of Milk
Microbiological and physicochemical analyses were performed
in commercial cow’s whole ESL milk whole and skim raw milk (the
latter was centrifuged at 6,0006g for 20 min to remove fat) and
whole and skim pasteurized milk supplied by a collaborating farm.
Samples of milk (500 ml) were aseptically sampled. Serial dilutions
of milk were made in quarter-strength Ringer solution (Oxoid,
Basingstoke, Hampshire, UK) and plated in duplicate on the
appropriate agar medium. Total bacterial counts were performed
in the different types of milk by deep-plating appropriate dilutions
on Plate Count Agar (32uC, 72 h). S. aureus counting was
performed as indicated above.
Total solids, fat and protein content were determined according
to the International Dairy Federation [40–42].
Protein Purification
Protein purification was performed as previously described [38].
Purity of each preparation was determined in 15% (w/v) SDS-
PAGE gels. Electrophoresis was conducted in Tris–Glycine buffer
at 20 mA for 1 h in the BioRad Mini-Protean gel apparatus.
Protein was quantified by the Quick Start Bradford Protein Assay
(BioRad, Hercules, CA). Quantification of lytic activity was
performed by turbidity reduction assays against live S. aureus Sa9
cells prepared as previously described [43,44].
Challenge Tests in Milk
HydH5, HydH5SH3b or HydH5Lyso proteins (3.5 mM),
CHAPSH3b protein (1 mM) and lysostaphin (1 mM) were individ-
ually added to 2 ml of whole ESL milk inoculated with 104 CFU/
ml of S. aureus Sa9 and incubated at 37uC for 6 h. CHAPSH3b
(1.65 mM) was also assayed at room temperature (RT) for the same
period. The anti-staphylococcal activity of CHAPSH3b (1.65 mM)
was further assayed in whole and skim raw milk and in whole and
skim pasteurized milk inoculated with 103 CFU/ml at 37uC and
RT for 2 h. Challenged milk without lytic protein additions were
used as controls.
Samples were taken at different times throughout the incubation
period and survival of S. aureus Sa9 was determined by serial
dilution plating onto Baird-Parker plates for ESL milk samples
(37uC, 48 h) and ChromoID S. aureus plates (37uC, 24 h) for raw
and pasteurized milk samples, respectively. ChromoID S. aureus is
a selective and differential culture medium for Staphylococcus sp, in
which different staphylococcal species are distinguished by the
colour of colonies (green for S. aureus; pink in S. saprophyticus; purple
in S. xylosus; white in S. epidermidis). This chromogenic medium
inhibits other Gram positive bacteria, Gram negative bacteria and
yeasts.
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CHAPSH3b Fusion Protein Stability in Milk
To test the stability of CHAPSH3b in milk, 1.65 mM protein
was added to 2 ml whole raw milk and kept at 4uC for 3 days.
Samples (250 mL) were taken every day, challenged with
103 CFU/ml of S. aureus Sa9 and incubated at RT for 15 min.
Staphylococcal viable counts in the presence and in the absence of
the antimicrobial protein were determined by serial dilution
plating onto ChromoID S. aureus plates. Results were expressed as
the percentage of viable counts reduction compared to the
untreated control.
CHAPSH3b Pasteurization Treatment
Commercial whole ESL milk and whole raw milk containing
CHAPSH3b (1.97 mM) were pasteurized (72uC, 15 s) in a thermo
cycler (BioRad Laboratories, Hercules, CA, USA). Samples were
cooled at RT for 15 min, further inoculated with 103 CFU/ml of
S. aureus Sa9 and incubated for 0, 15, 30, 60 and 120 minutes at
RT. Staphylococcal viable counts were determined as indicated
above and results also expressed as the percentage reduction of
viable counts.
Statistical Analysis
Statistical analysis was performed using the SPSS-PC +11.0
software (SPSS, Chicago, IL, USA). Staphylococcal CFU data
were subjected to one-way ANOVA within each sampling time.
Types of anti-staphylococcal protein (HydH5, HydSH3b, HydH5-
lyso and CHAPSH3b) were compared against the untreated
control. Data of cold storage stability of protein CHAPSH3b were
compared with one-way ANOVA and the LSD test was used for a
comparison of means at a level of significance P,0.05.
Results
Microbiological and Physicochemical Characteristics of
Milk
Total viable bacterial counts were below the detection limit
(,10 CFU/ml) in ESL milk, whereas about 7.086104 CFU/ml
and 3.896101 CFU/ml were detected in raw and pasteurized
milk, respectively. Viable counts were lower in both raw skim
(1.906103 CFU/ml); and pasteurized skim milk (1.206101 CFU/
ml). S. aureus counts were only detected in whole raw milk (2.84–
4.06101 CFU/ml) and they kept below 102 CFU/ml throughout
2 h of incubation.
Results of gross composition are shown in Table 1. Mean values
of total solids, fat and protein contents of whole commercial ESL
milk, and raw (whole and skim) and pasteurized (whole and skim)
milk were within the standards of commercial and farmhouse milk.
HydH5 and its Derivative Fusion Proteins have
Antimicrobial Activity against S. aureus Sa9 in
Commercial ESL Milk
The antimicrobial activity of HydH5, its derivative fusion
proteins and lysostaphin was assessed in commercial whole ESL
milk inoculated with 104 CFU/ml of S. aureus Sa9. The effect of
the different proteins on S. aureus growth was first tested at 37uC.
In the absence of antimicrobial proteins (control cultures) the
staphylococcal strain grew from 104 to 6.56104 CFU/ml during
the first hour of incubation with a more robust increase in CFU
subsequently, achieving 8.96107 CFU/ml at the end of six hours
(Fig. 1A). The addition of HydH5, HydH5SH3b and HydH5Lyso
(3.5 mM) to the S. aureus inoculated milk resulted in an immediate
effect on S. aureus viability, with the viable counts maintained
below the time zero control counts (immediately after addition of
the antimicrobials). At time 0, only the viable counts in
HydH5Lyso treated cultures were significantly different (P,0.05)
compared to the control cultures. From 15 min onwards, the
inhibitory effect of each of the proteins on S. aureus viability was
significant (P,0.01 at 15 min and P,0.001 thereafter). The
greatest reduction in viable counts (about 2.3460.01 log CFU/ml)
was detected at the end of the 6 h incubation period (Fig. 1A).
These activities are, however, far from lysostaphin antistaphylo-
coccal activity since 1 mM of this bacterial peptide resulted in an
immediately kill of the S. aureus population and no viable counts
were detected even at time 0. In addition, no-re-growth was
observed afterwards (data not shown). Only the fusion protein
CHAPSH3b showed an inhibitory effect on S. aureus similar to
lysostaphin since 1 mM resulted in a complete clearance of the
pathogen 15 min after addition without further re-growth
throughout the assay period (6 h) (Fig. 1A). Likewise, viable
counts became undetectable immediately after the addition of
1.65 mM CHAPSH3b (data not shown). At RT, the inhibitory
effect of CHAPSH3b decreased slightly with a higher protein
concentration (1.65 mM) required to fully eliminate S. aureus in
15 min after addition (Fig. 1B), whereas a continuous proliferation
of the staphylococcal population occurred in the control cultures.
CHAPSH3b Fusion Protein is Effective in Raw Milk and
Highly Effective in Pasteurized Milk
The effect of the CHAPSH3b protein was tested against S.
aureus Sa9 strain (103 CFU/ml) in whole and skim raw milk at
both 37uC and RT. As shown in Figure 2A, the staphylococcal
growth observed in the whole raw milk control cultures was
immediately inhibited by addition of 1.65 mM of CHAPSH3b as
no viable counts were detected at 37uC or RT and re-growth was
prevented for ,30 min of incubation. Thereafter, S. aureus growth
was observed at both temperatures but CHAPSH3b treatment
kept viable counts below the control counts throughout the 2 h
experiment. CHAPSH3b showed higher growth inhibition at RT
than at 37uC (Fig. 2A). Significant differences between control and
treated cultures were observed throughout the remaining 2 h
incubation period at both RT (P,0.001) and 37uC (P,0.001 at
30 min and P,0.01 at 60 and 120 min of sampling time). At the
end of the incubation period, the presence of the antimicrobial
protein resulted in a reduction of 1.0960.12 and 0.760.17 log
CFU/ml at RT and 37uC, respectively, compared to the control
cultures. The level of indigenous S. aureus in raw milk was also
monitored through the incubation period as an additional control.
This population remained below 102 CFU/ml and was also
Table 1. Gross composition of milk used in the HydH5 and its
derivative fusion proteins antistaphyloccal assaysa.
ESLb Whole Skim
Raw Pasteurized Raw Pasteurized
Total
solidsc
12.2860.08 11.1460.01 11.1760.03 11.0460.12 11.0160,09
Fatd 3.5460.02 3.1860.03 3.2060.05 0.160.02 0.1560.04
Proteind 3.0660.09 3.0960.12 3.0960.14 3.0760.12 3.0860.16
aData reported are means 6standard deviations of two independent milk
samples.
bESL: extended shelf life milk.
cTotal solids: data expressed as g/100 g milk.
dFat/Protein: expressed as g/100 g milk.
doi:10.1371/journal.pone.0054828.t001
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sensitive to CHAPSH3b (data not shown).Similar staphylococcal
growth kinetics was observed in skim raw milk in the presence of
CHAPSH3b (Fig. 3A). As in whole milk (Fig. 2), re-growth also
occurred after 30 min and the antimicrobial protein exhibited
higher inhibitory activity at RT. Differences in staphylococcal
viable counts between VAPGH-treated and control samples were
significant (P,0.001) at both 37uC and RT. The final reduction in
staphylococcal CFU was similar at 37uC (0.7560.23 log CFU/ml)
and lower (0.4160.09 log CFU/ml) at RT than in whole raw milk
(Fig. 3A).
CHAPSH3b was more effective in reducing S. aureus Sa9 in
pasteurized milk (whole and skim) as is shown in Figure 2B and
3B. At RT, CHAPSH3b (1.65 mM) was able to reduce S. aureus
viable counts to undetectable levels in whole and skim milk
immediately after addition, and no re-growth was detected for 2 h
thereafter. At 37uC, the presence of CHAPSH3b prevented
staphylococcal re-growth for over 30 min in whole milk and for
more than 1 h in skim milk. At the end of the incubation period,
the final staphylococcal population in whole and skim pasteurized
milk was 0.7560.23 (P,0.001) and 2.0260.21 log CFU/ml
(P,0.001) lower than the control, respectively, in the presence of
CHAPSH3b. In order to rule out the possibility of CHAPSH3b-
resistant colonies confounding the data, ten S. aureus colonies were
randomly selected from the selective agar plates used for viable
count determination. Turbidity reduction assays of each colony
performed in the presence of 1 mM of CHAPSH3b indicate that
all were sensitive to lysis by CHAPSH3b to the same extent as the
inoculated strain (data not shown).
CHAPSH3b Remains Active after Storage at 4uC in Milk
and after Pasteurization Treatment
To assess the CHAPSH3b stability in milk, challenge assays
were performed after storage of the protein (1.65 mM) in
refrigerated raw milk for 3 days. As shown in Figure 4A, the
non cold-stored protein reduced the initial staphylococcal popu-
lation (103 CFU/ml) by 94% after just 15 min at RT. The
inhibitory activity of CHAPSH3b decreased significantly (P,0.05)
with the cold storage time as compared with the non-cold stored
protein but the remaining activity was still able to kill 42%, 33%
and 32% of the S. aureus population following storage in milk at
4uC for one, two and three days, respectively. No significant
differences in the anti-staphylococcal activity after 2 and 3 days of
cold storage were detected (P.0.05). To test the stability of
CHAPSH3b under high temperature treatment, the protein
(2 mM) was subjected at pasteurization (72uC, 15 s) in both
commercial ESL whole milk and raw whole milk and further
challenged with S. aureus at RT. Pasteurization in ELS milk did not
Figure 1. Antimicrobial activity of HydH5, lysostaphin, and its derivative fusion proteins in commercial whole ELS milk. Milk was
inoculated with 104 CFU/ml of S. aureus Sa9 and incubated for 0, 15, 30 min, 1, 2, 4 and 6 h at 37uC either without lytic protein (control; dark grey
bars) or in the presence of : A) 1 mM CHAP-SH3b (light grey bars), and 3.5 mM HydH5 (stippled bars), 3.5 mM HydH5SH3b (black bars) and 3.5 mM
HydH5Lyso (diagonal stripes bars); 1 mM lysostaphin (gross line on X axis); (B) 1.65 mM CHAPSH3b (light grey bars), control without protein (dark grey
bars), at room temperature. Values expressed as log10 CFU/ml are the means 6 standard deviations of two independent experiments. Bars having an
asterisk are significantly different from the control (*P#0.05). S. aureus detection threshold (,10 CFU/ml).
doi:10.1371/journal.pone.0054828.g001
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affect the inhibitory activity of CHAPSH3b since no viable counts
were detected in treated cultures throughout the incubation period
(Fig. 4B). However, the heat treatment in raw milk clearly reduced
CHAPSH3b activity as only partial inhibition of S. aureus CFUs
was observed in the first 15 min of treatment (Fig. 4B) compared
to the undetectable CFUs that was observed in untreated raw milk
cultures spiked with a lower concentration (1.65 mM) of unpas-
teurized protein (Fig. 2A). Nevertheless, the reductions in viable
counts between control and treated cultures were significant
throughout the incubation period (P,0.001 at time 0 and 60 min;
P,0.01 at time 15, 30 and 120 min).
Discussion
Current food safety depends on a combination of preventive
hygiene-based approaches that are focused on minimizing the
microbial contamination of raw material that mainly include
physical and chemical decontamination treatments aimed to
remove the microbial contamination in food products [45]. Due
to the increasing consumer demand for natural, nutritious and
fresh-tasting foods, the food industry is interested in replacing
traditional preservation techniques (e.g. heat and chemical
treatments) whenever possible, to avoid the risk of sensory quality
changes or the presence of unwanted chemical residues in foods
[46]. Food preservation treatments based on natural antimicrobi-
als such as bacteriocins, bacteriophages or phage-derived lytic
enzymes could help to fight against pathogenic and spoilage
bacteria along the food chain and are not expected to alter the
sensory change or other undesirable effects of traditional
treatments [24]. The application of bacteriocins in food safety
has been widely studied for the last two decades [47], but food
biopreservation based on phages and phage-derived lytic enzymes
is a more recent avenue of research [48]. So far, phage derived
lysins have been mainly assayed in veterinary and human medical
model approaches [12,49], and less attention has been paid to
their potential role as food biopreservatives [50]. Nevertheless,
some phage lytic enzymes have shown antibacterial activity in
milk. This is true for S. aureus bacteriophage vB_SauS-phiIPLA88
endolysin LysH5 that completely inhibited S. aureus growth in
commercial pasteurized milk after 4 h of treatment [26], or the
fusion proteins lSA2-E-Lyso-SH3b (streptococcal lSA2 endolysin
endopeptidase domain fused to the lysostaphin SH3b domain) and
lSA2-E-LysK-SH3b (streptococcal lSA2 endolysin endopeptidase
domain fused to the staphylococcal phage K endolysin SH3b
domain) that showed anti-staphylococcal activity in ultra-high
Figure 2. Antimicrobial activity of CHAPSH3b fusion protein in whole milk. Milk was inoculated with 103 CFU/ml of S. aureus Sa9 and
incubated in the presence of 1.65 mM CHAPSH3b for 0, 15, 30, 60 and 120 min either at RT or 37uC in: A) raw milk and B) pasteurized milk. Dark grey
bars indicate S. aureus Sa9 control culture and light grey bars S. aureus Sa9+ CHAPSH3b. Values, expressed as log CFU/ml, are the means 6 standard
deviations of two independent experiments. Bars having asterisks are significantly different from the control (**P,0.01; ***P,0.001). S. aureus
detection threshold (,10 CFU/ml).
doi:10.1371/journal.pone.0054828.g002
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temperature (UHT) milk by reducing the bacterial load by 3 and 1
log CFU/ml, respectively, within 3 h of incubation [51]. Recently,
it has been also reported that Listeria bacteriophage endolysin
LysZ5 was able to kill 4 log CFU/ml of L. monocytogenes within 3 h
at 4uC in soya milk [52].
The peptidoglycan hydrolase HydH5 encoded by the S. aureus
phage vB_SauS-phiIPLA88 [37] and the fusion proteins between
HydH5 and lysostaphin (CHAPSH3b, HydH5SH3b and HydH5-
Lyso) have all been shown to yield staphylolytic activity in
zymogram, plate lysis and turbidity reduction assays [38]. In this
work, these constructs have been assessed as antimicrobial
additives for preventing the growth of S. aureus in milk. HydH5,
HydH5SH3b and HydH5Lyso showed staphylolytic activity in
commercial whole ESL milk but were clearly less effective than
lysostaphin and CHAPSH3b activities. Lysostaphin and
CHAPSH3b (1 mM) were able to reduce the S. aureus load by 4-
log CFU/ml immediately or 15 min after addition at 37uC,
respectively, while nearly four times as much (3.5 mM) of the other
constructs were needed to obtain just a reduction of the
staphylococcal counts throughout the incubation period compared
to the untreated cultures.
These findings are consistent with our previous results. In fact,
the CHAP domain of HydH5 when fused to the lysostaphin SH3b
domain showed a 4.8-fold higher activity, compared to full length
HydH5 [38]. The high activity shown by CHAPSH3b in ESL
milk, prompted us to broaden the assays on milk with a broader
range of treatments. Accordingly, CHAPSH3b activity was
assessed in raw (whole and skim) and pasteurized (whole and
skim) milk.
CHAPSH3b is active in whole and skim raw milk at 37uC and
RT, as the protein was able to reduce 103 CFU/ml below the
detection limit (,10 CFU/ml) for 30 min. The staphylolytic
activity, however, was lower than in high-heat treated milk
yielding less of a reduction in viable counts, despite a higher
concentration of enzyme (1.65 mM versus 1 mM). Of note, the
indigenous S. aureus contamination of raw milk do not seem to
have interfered in the CHAPSH3b activity because it was shown
to be sensitive and hardly accounts for the total S. aureus population
once Sa9 was added. Pasteurization of milk clearly enhanced
CHAPSH3b staphylolytic activity in both whole and skim milk at
both temperatures. Apparently, something in the raw milk is
hampering the CHAPSH3b activity. One possibility is heat-
sensitive components such as immunoglobulin M and agglutinins
Figure 3. Antimicrobial activity of CHAPSH3b protein in skim milk. Milk was inoculated with 103 CFU/ml of S. aureus Sa9 and incubated in
the presence of 1.65 mM CHAPSH3b for 0, 15, 30, 60 and 120 min either at RT or 37uC in: A) raw milk and B) pasteurized milk. Dark grey bars indicate
S. aureus Sa9 control culture and light grey bars S. aureus Sa9+ CHAPSH3b. Values, expressed as log CFU/ml, are the means 6 standard deviations of
two independent experiments. Bars having asterisks are significantly different from the control (***P,0.001). S. aureus detection threshold (,10 CFU/
ml).
doi:10.1371/journal.pone.0054828.g003
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in so far as they have been reported to promote the formation of
cell clumps [53] that would likely make it more difficult for the
antibacterial protein to reach the staphylococcal cells sequestered
inside the clumps. These components of raw milk have also been
previously reported to hamper phage adsorption [54]. In contrast,
CHAPSH3b activity does not seem to be affected by fat globules in
milk since similar kinetics of staphylococcal inhibition were
observed in whole or skim milk despite the fact that bacterial
clumps have also been associated with fat globules [55].
Although structural and chemical composition of food can
negatively affect the ability of antimicrobials to reach the pathogen
[56], the addition of CHAPSH3b to different types of milk yielded
an immediate reduction in S. aureus viable counts with the only
exception being heat-treated protein in raw milk. This suggests a
quick reaction to CHAPSH3b which is reminiscent with previous
data with Listeria monocytogenes phage endolysins Ply118 and Ply500.
The cell binding domain of these proteins showed a rapid and
saturation-dependent binding to L. monocytogenes cell surface within
15 s, with no further increase [57]. A high affinity for staphylo-
coccal cells, especially MRSA, was also described for the endolysin
LysGH15 [17]. The staphylococcal re-growth observed at latter
sampling times could be attributed to those cells that were
sequestered and did not see the CHAPSH3b at the beginning of
the treatment. However, it should be noted that the number of
bacteria attained by the end of the assay period (clearly below the
critical threshold of 105 CFU/ml for production of hazardous
enterotoxins levels to consumers) does not present a high-risk of
enterotoxin contamination of milk [58]. In addition, no
CHAPSH3b resistant bacteria were isolated from lysin-treated
milk. Therefore, insensitivity to CHAPSH3b appears to be a rare
event under the experimental conditions tested. Other researchers
also failed to detect resistance against endolysins used to control
the growth of Gram positive bacteria, such as Bacillus anthracis [59]
and Streptococcus pneumoniae [14].
Of note, CHAPSH3b showed higher activity at RT than at
37uC in raw and pasteurized milk. The lower growth rate of S.
aureus at RT could account for the higher effectiveness of
CHAPSH3b. The demonstrated 3 day longevity of CHAPSH3b
in cold milk supports the notion of using CHAPSH3b as a
potential staphylolytic agent to prevent S. aureus development
during an unexpected breakdown in cold storage and thus,
enhance food safety.
Figure 4. Cold storage stability and pasteurization resistance of CHAPSH3b in milk. A) 1.65 mM CHAPSH3b was stored in raw milk at 4uC
for 3 days. Samples were taken every day, inoculated with 103 CFU/ml of S. aureus Sa9 and incubated for 15 min at room temperature before plating.
Non-cold storage protein was used as control. Cold storage stability was expressed as the percentage reduction of S. aureus Sa9 CFU/ml after
CHAPSH3b addition. Values are the means 6 standard deviations of two independent experiments. Bars having different letters are significantly
different (P,0.05). B) 1.97 mM CHAPSH3b was pasteurized at 72uC for 15 s in raw milk (left) and commercial pasteurized milk (right). Samples were
inoculated with 103 CFU/ml and incubated for 0, 15, 30, 60 and 120 min at room temperature before plating. S. aureus inoculated cultures without
lytic protein addition were used as control (dark grey bars). Light grey bars indicate S. aureus Sa9+ CHAPSH3b. Data from pasteurized samples with
CHAPSH3b activity was expressed as log CFU/ml. Values are the means6 standard deviations of two independent experiments. Bars having asterisks
are significantly different from the control (**P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0054828.g004
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The ability of CHAPSH3b (1.65 mM) to kill up to 103 CFU/ml
in raw milk in the first 30 min of treatment at 37uC along with its
proven activity against MRSA strains [38] points to CHAPSH3b
as a potential candidate to control S. aureus infections in cows’
mammary glands. Previous reports have shown the effectiveness of
chimeric phage lysins to kill mastitis-causing S. aureus in murine
mammary glands [25]. The safety of endolysins has also been
determined since experimental mice to which endolysin was
administered did not exhibit adverse physiological effects [60].
The stability of CHAPSH3b after exposure at high tempera-
tures (72uC, 15 s) and cold storage in milk has a clear technical
interest for dairy products protection since this staphylolytic
protein could be added to raw milk before thermal processing to
control any potential contamination by S. aureus. CHAPSH3b
thermostability is consistent with our previous results which
showed that HydH5 retained activity after heat treatment (5 min
treatment at 100uC) [37]. Recently, Listeria bacteriophage pepti-
doglycan hydrolases also revealed a high thermostability retaining
up to 35% activity after 30 min of incubation at 90uC [51]. By
contrast, the lytic activity of some phage endolysins was destroyed
by heat treatment [26,61]. However, none of these assays were
performed in milk, work that is sorely needed.
Regarding the lytic proteins’ stability in cold storage, prior to
this study, the existing data were obtained in aqueous solutions but
not in milk. This is the case for CHAPk that retained up to 70% of
its lytic activity after being stored at 4uC for one month [18]. By
contrast, the remaining lytic activity of CHAPSH3b was ,33%
after 3 days of storage a 4uC in raw milk. As indicated above, the
reduction of lytic activity in raw milk could be due to the presence
of heat-sensitive components in raw milk that hamper the access of
the lytic protein to its target on the cell wall of the bacterial host
[56]. Increasing the concentration of the lytic protein might enable
us to overcome this limited activity in raw milk. Indeed, 3.30 mM
(100 mg/ml) CHAPSH3b was able to kill 103 CFU/ml of S. aureus
in raw milk and no re-growth was observed within 2 h (data not
shown).
Our findings demonstrate the ability of HydH5-derived proteins
to inhibit the development of S. aureus in milk, with CHAPSH3b
being particularly effective. The high anti-staphylococcal activity
of CHAPSH3b along with its thermostability might enable this
protein to be applied directly to raw milk after milking. Overall,
our results suggest that phage lytic proteins might be useful as a
valuable hurdle to prevent S. aureus growth in milk and presumably
in other dairy products.
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